Patents by Inventor Anne-Marie Duliege

Anne-Marie Duliege has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD AND COMPOSITION EMBODIMENTS FOR TREATING ACUTE MYELOID LEUKEMIA
    Publication number: 20220000880
    Abstract: Disclosed herein are embodiments of a method and pharmaceutical composition for treating acute myeloid leukemia (AML). In particular, the method embodiments comprise treating AML with 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one, or a prodrug thereof, alone or in combination with one or more therapeutic agents that themselves are effective for treating AML. Also disclosed are embodiments of a pharmaceutical composition comprising 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one, or a prodrug thereof, either as the sole therapeutic agent or in combination with one or more therapeutic agents effective for treating AML.
    Type: Application
    Filed: October 31, 2019
    Publication date: January 6, 2022
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Sandra Tong, Vadim Markovtsov, Ann Lowe, Anne-Marie Duliege
  • Erythropoietin receptor peptide formulations and uses
    Patent number: 8324159
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
    Type: Grant
    Filed: July 23, 2008
    Date of Patent: December 4, 2012
    Assignee: Affymax, Inc.
    Inventors: Anne-Marie Duliege, Richard Stead, Kerstin Leuther, Kathryn Wynne Woodburn, Robert Barnett Naso
  • Erythropoietin receptor peptide formulations and uses
    Patent number: 7919461
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: April 5, 2011
    Assignee: Affymax, Inc.
    Inventors: Anne-Marie Duliege, Richard Stead, Kerstin Leuther, Kathryn Wynne Woodburn, Robert Barnett Naso
  • Erythropoietin receptor peptide formulations and uses
    Patent number: 7906485
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production, including pure red cell aplasia (PRCA). Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
    Type: Grant
    Filed: June 5, 2006
    Date of Patent: March 15, 2011
    Assignee: Affymax, Inc.
    Inventors: Anne-Marie Duliege, Richard Stead, Kerstin Leuther, Kathryn Wynne Woodburn, Robert Barnett Naso
  • ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES
    Publication number: 20090221510
    Abstract: The present invention relates to novel uses of peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to methods of using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production, including chemotherapy induced anemia. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided. Also provided are kits and articles of manufacture comprising such compounds.
    Type: Application
    Filed: August 21, 2008
    Publication date: September 3, 2009
    Inventors: RICHARD STEAD, ANNE-MARIE DULIEGE, ROBERT HONG CHOON LEONG, JULIA IWASHITA, WILLIAM LANG, MARK A. WEINBERG
  • TREATMENT OF ANTI-ERYTHROPOIETIN ANTIBODY-MEDIATED DISORDERS WITH SYNTHETIC PEPTIDE-BASED EPO RECEPTOR AGONISTS
    Publication number: 20090209457
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat or to prevent anti-erythropoietin (EPO) antibody-mediated disorders such as pure red cell aplasia (PRCA) that are characterized by anti-EPO antibodies. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: February 13, 2009
    Publication date: August 20, 2009
    Applicant: Affymax, Inc.
    Inventors: Anne-Marie Duliege, Peter J. Schatz, Richard Stead, Kathryn Wynne Woodburn
  • Erythropoietin receptor peptide formulations and uses
    Patent number: 7550433
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: June 23, 2009
    Assignee: Affymax, Inc.
    Inventors: Anne-Marie Duliege, Richard Stead, Kerstin Leuther, Kathryn Woodburn, Robert Barnett Naso
  • ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES
    Publication number: 20090136442
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
    Type: Application
    Filed: June 5, 2006
    Publication date: May 28, 2009
    Applicant: AFFYMAX, INC.
    Inventors: Anne-Marie Duliege, Richard Stead, Kerstin Leuther, Kathryn Wynne Woodburn, Robert Barnett Naso
  • ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES
    Publication number: 20090118183
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
    Type: Application
    Filed: July 23, 2008
    Publication date: May 7, 2009
    Applicant: Affymax, Inc.
    Inventors: Anne-Marie Duliege, Richard Stead, Kerstin Leuther, Kathryn Wynne Woodburn, Robert Barnett Naso
  • ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES
    Publication number: 20080081783
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
    Type: Application
    Filed: July 13, 2007
    Publication date: April 3, 2008
    Applicant: AFFYMAX, INC.
    Inventors: Anne-Marie Duliege, Richard Stead, Kerstin Leuther, Kathryn Woodburn, Robert Naso
  • Erythropoietin receptor peptide formulations and uses
    Publication number: 20070104704
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
    Type: Application
    Filed: June 2, 2006
    Publication date: May 10, 2007
    Applicant: Affymax, Inc.
    Inventors: Anne-Marie Duliege, Richard Stead, Kerstin Leuther, Kathryn Woodburn, Robert Naso